RTS,S/AS Vaccine Induces Protective Immunity Linked to CD4+ T Cells
Author Information
Author(s): Lumsden Joanne M., Schwenk Robert J., Rein Lisa E., Moris Philippe, Janssens Michel, Ofori-Anyinam Opokua, Cohen Joe, Kester Kent E., Heppner D. Gray, Krzych Urszula
Primary Institution: Walter Reed Army Institute of Research
Hypothesis
Does the RTS,S vaccine induce effector and central memory CD4+ T cells that contribute to protective immunity against malaria?
Conclusion
The RTS,S/AS vaccine induces higher frequencies of IL-2-producing CD4+ T cells in protected individuals compared to non-protected individuals.
Supporting Evidence
- 40% of subjects showed sterile immunity against malaria after vaccination.
- IL-2-producing CD4+ T cells were significantly higher in protected subjects.
- Total numbers of IL-2-producing CD4+ TCM and TE/EM cells correlated with protection.
- Significant differences in cytokine production were observed between protected and non-protected individuals.
- IL-2 levels correlated with CSP-specific antibody titers.
Takeaway
The RTS,S vaccine helps the body create special immune cells that can fight malaria, and more of these cells are found in people who are protected from the disease.
Methodology
The study involved a phase 2a double-blind, randomized trial where 80 healthy malaria-naïve adults received the RTS,S/AS vaccine and were later challenged with malaria.
Potential Biases
Potential conflicts of interest due to authors' affiliations with GlaxoSmithKline.
Limitations
The study's findings may not be generalizable to populations outside the trial's demographic.
Participant Demographics
80 healthy malaria-naïve adults.
Statistical Information
P-Value
p<0.003 for CD4+ TCM; p<0.015 for CD4+ TE/EM
Confidence Interval
95%
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website